


SUPPORTING EFFORTS TO ACCELERATE THE UNDERSTANDING OF THE MOLECULAR BASIS OF CANCER THROUGH THE APPLICATION OF LARGE-SCALE PROTEOGENOMICS

OVERVIEW

Since 2016 Fidelis Research has been a tissue sourcing partner in a large-scale project for the NIH's National Cancer Institute in an effort to understand the molecular basis of cancer that is not fully elucidated or not possible through genomics and to accelerate the translation of molecular findings.

Fidelis has activated collections in Bulgaria, Romania, Serbia and Turkey and as of today there are more than 15 active sites, daily collections and regular shipments. Samples are collected, immediately prepared for medium-term storage in a biobank facility and periodically shipped to the United States with dry shippers on vapor phase liquid nitrogen (LN₂).



List of tumor indications collected for described study

COLLECTION DETAILS

Each solid tumor case (i.e. patient donor) includes the collection of tumor tissue and normal adjacent tissue, as well as whole blood, while Acute Myeloid Leukemia (AML) cases comprise whole blood and **bone marrow** aspirate. The material shipped for each solid tumor case includes **whole blood** frozen immediately after collection, **tumor tissue** – part aliquoted and frozen in LN₂ and part formalin-fixed paraffin embedded (**FFPE blocks** and **slides**), as well as **normal adjacent tissue (NAT)** prepared in the same way, or **PBMCs** and **BMMCs** for the AML cases.

Donor	Solid tumors	Tumor tissue + NAT	FFPE blocks + NAT	Whole Blood
	AML	PBMCs		BMMCs

IN NUMBERS

1000+

cases collected

20+

active collection sites with multiple PIs

20+

indications with new ones added

4

countries for maximum coverage